OIM
SWTX

Oracle Investment Management’s SpringWorks Therapeutics SWTX Stock Holding History

Oracle Investment Management’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-531,351
Closed -$23.6M – 17
2025
Q1 		$23.4M Buy
531,351
+276,578
+109% +$12.7M 11.83% 2
2024
Q4 		$9.2M Buy
254,773
+220,573
+645% +$7.71M 5.01% 5
2024
Q3 		$1.1M Sell
34,200
-199,000
-85% -$7.44M 0.66% 17
2024
Q2 		$8.78M Sell
233,200
-188,383
-45% -$7.93M 8.2% 4
2024
Q1 		$20.8M Buy
421,583
+264,500
+168% +$12.2M 13.79% 2
2023
Q4 		$5.73M Buy
+157,083
New +$4.1M 3.49% 10
2023
Q2 		– Sell
-43,500
Closed -$1.12M – 35
2023
Q1 		$1.12M Buy
+43,500
New +$1.27M 1.08% 14

Other funds holding SWTX

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Oracle Investment Management's SWTX Position: Q2 2025 in Review

Oracle Investment Management sold out of SpringWorks Therapeutics (SWTX) in Q2 2025, closing a stake of 531,351 shares — an estimated $23.6M sold.

Oracle Investment Management first reported a position in SWTX in Q1 2023 and held it in 7 quarters. The position peaked at $23.4M in Q1 2025. 222 funds tracked by Wall St. Rank hold SWTX as of Q2 2025.

  • Oracle Investment Management reported no remaining SpringWorks Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Oracle Investment Management sold 531,351 SpringWorks Therapeutics shares in Q2 2025, an estimated $23.6M.
  • Oracle Investment Management first reported a position in SpringWorks Therapeutics in Q1 2023 and held it in 7 quarters.
  • Oracle Investment Management's SpringWorks Therapeutics position peaked at $23.4M in Q1 2025.
  • 222 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2025.

Based on Oracle Investment Management's 13F filing for Q2 2025, filed 15 Aug 2025.